Ivacaftor + tezacaftor

Trade Name:

Symdeko

Manufacturer/Distributor:

Vertex Pharmaceuticals

Classification:

Cystic Fibrosis Transmembrane Conductance Regulator Correctors and Potentiators

ATC Class:

R07AX31 - ivacaftor + tezacaftor

Status:

active

Notice of Compliance (yyyy/mm/dd):

2018/06/27

Date Marketed in Canada (yyyy/mm/dd):

2018/06/27

Presentation:

Tablet: 150 mg ivacaftor plus 100 mg tezacaftor. Tablet: 150 mg ivacaftor. DIN: 02478080

Comments:

For treatment of patients with cystic fibrosis aged 12 years and older with mutation in the CFTR gene. Dose is fixed dose regimen (150 mg/100 mg) in the morning and 150 mg ivacaftor in the evening.

Source:

Product monograph

Keywords:

ivacaftor

Keywords:

tezacaftor

Keywords:

cystic fibrosis

Access:

public

Back to:

Please note - this is not a complete list of products available in Canada. For a complete list of drug products marketed in Canada, visit the Health Canada Drug Product Database

A (37) | B (20) | C (24) | D (37) | E (40) | F (12) | G (11) | H (9) | I (24) | K (1) | L (26) | M (12) | N (7) | O (12) | P (28) | R (14) | S (27) | T (33) | U (4) | V (13) | W (2) | Z (4)

Generic Name	Common Trade Name(s)	Classification	Date Marketed in Canada (yyyy/mm/dd)
Doravirine + Lamivudine + Tenofovir	Delstrigo	Antiviral agent	2018/12/15
Doripenem	Doribax	Antibacterial agent	2009/09
Doxepin	Silenor	Hypnotic	2012/01/08
Dronabinol	Marinol	Antiemetic	2012/02/24
Dronedarone	Multaq	Antiarrhythmic agent	2009/08/14
Drospirenone + estetrol	Nextstellis	Oral contraceptive	2021/06/15
Drotrecogin alfa	Xigris	Antithrombotic profibrinolytic anti-inflammatory enzyme	2011/10/25
Dulaglutide	Trulicity	Antihyperglycemic agent	2016/01/08
Dupilumab	Dupixent	Skin and mucous membrane agent	2017/11/30
Dutasteride + tamsulosin	Jalyn	Alpha-1 blocker + 5-Alpha reductase inhibitor	2012/02/03
Eculizumab	Soliris	Humanized monoclonal antibody	2009/06/29
Edaravone	Radicava	Treatment for amyotrophic lateral sclerosis	2019/10/29
Edoxaban	Lixiana	Anticoagulant	2017/01
Elagolix	Orilissa	Gonadotropin releasing hormone receptor antagonist	2018/10/31
Elbasvir + grazoprevir	Zepatier	Antiviral agent	2016/02/02
Elexacaftor + tezacaftor + ivacaftor	Trikafta	Cystic fibrosis transmembrane conductance regulator correctors	2021/06/22
Eltrombopag	Revolade	Thrombopoietin receptor antagonist	2011/0404
Eluxadoline	Viberzi	Miscellaneous GI drug	2017/05
Eluxadoline	Viberzi	Miscellaneous GI drugs	2017/04/24
Elvitegravir + cobicistat + emtricitabine + tenofovir alafenamide	Genvoya	Antiretroviral agents	2016/02/03
Elvitegravir + Cobicistat + Emtricitabine + Tenofovir disoproxil fumarate	Stribild	Antiretroviral agent	2012/12/20
Empagliflozin	Jardiance	Sodium-glucose contransporter 2 (SGLT2) inhibitor	2015/08/11
Empagliflozin + linagliptin	Glyxambi	Antidiabetic agent	2016/12/15
Empagliflozin + metformin	Synjardy	Oral blood glucose lowering agents	2017/09/18
Emtricitabine + tenofovir	Descovy	Antiretroviral agent	2016/06/03
Enasidenib	IDHIFA	Antineoplastic agent / IDH2 Inhibitor	2019/02/27
Entrectinib	Rozlytrek	Antineoplastic agent
Enzalutamide	Xtandi	Antineoplastic agent	2013/06/07
Eplerenone	Inspra	Aldosterone antagonist	2009/02/26
Eptinezumab	Vyepti	Prevention of migraine; calcitonin gene-related peptide binding antibody	2021/01/11
Erdafitinib	Balversa	Protein kinase inhibitor	2019/12/09
Erenumab	Aimovig	Anti-calcitonin gene-related peptide receptor	2018/08/01
Eribulin	Halaven	Antineoplastic agent	2012/03/10
Ertugliflozin	Steglatro	Sodium-glucose co-transporter 2 (SGLT2) inhibitor	2018/05/23
Ertugliflozin + metformin	Segluromet	Oral blood glucose lowering agents	2018/05/30
Ertugliflozin + sitagliptin	Steglujan	Oral blood glucose lowering agents	2018/05/22